These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1331443)

  • 1. A study of the effects of lisinopril when used in addition to atenolol.
    Soininen K; Gerlin-Piira L; Suihkonen J; Kyllönen T; Parviainen R; Kyllönen E; Hämäläinen K; Lonka R; Tikkanen T; Selonen R
    J Hum Hypertens; 1992 Aug; 6(4):321-4. PubMed ID: 1331443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE inhibitors in mild to moderate hypertension: comparison of lisinopril and captopril administered once daily. French Cooperative Study Group.
    Gosse P; Dallocchio M; Gourgon R
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():23-8. PubMed ID: 2550642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension.
    Whelton A; Dunne B; Glazer N; Kostis JB; Miller WE; Rector DJ; Tresznewsky ON
    J Hum Hypertens; 1992 Aug; 6(4):325-31. PubMed ID: 1331444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double blind comparison of perindopril and atenolol in essential hypertension.
    Thurston H; Mimran A; Zanchetti A; Creytens G; Rorive G; Brown CL; Santoni JP
    J Hum Hypertens; 1990 Oct; 4(5):547-52. PubMed ID: 2283644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which anti-hypertensive to add to a beta-blocker: ACE inhibitor or diuretic?
    Huttunen M; Lampainen E; Lilja M; Ikäheimo M; Kontro J; Mäkynen P; Savolainen A
    J Hum Hypertens; 1992 Apr; 6(2):121-5. PubMed ID: 1350796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril.
    Bursztyn M; Gavras I; Gourley L; DeSilva J; Whalen J; Gavras H
    Clin Ther; 1994; 16(3):429-36. PubMed ID: 7923309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. The Cooperative Study Group.
    Witchitz S; Serradimigni A
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():29-33. PubMed ID: 2550643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisinopril versus slow release nifedipine in patients with essential hypertension: a multicentre study.
    Predel HG; Kramer HJ
    J Hum Hypertens; 1994 Oct; 8(10):777-80. PubMed ID: 7837215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The results of a large multicentre study comparing low-dose lisinopril-hydrochlorothiazide with the monocomponents.
    Lang H
    J Hum Hypertens; 1991 Dec; 5 Suppl 2():73-6. PubMed ID: 1665182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinapril versus atenolol in the treatment of mild to moderate essential hypertension.
    Bahena JH; Estrella ME; Muñoz M
    Clin Ther; 1992; 14(4):527-36. PubMed ID: 1525787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lisinopril or lisinopril/hydrochlorothiazide compared with adjusting of previous medication and intensifying non-pharmacological treatment in patients with mild to moderate hypertension.
    Keinänen-Kiukaanniemi S; Rasmusen M; Pekkarinen T; Pitkäjärvi T; Romo M; Takala J
    Arzneimittelforschung; 1997 Feb; 47(2):144-50. PubMed ID: 9079233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. The United Kingdom Lacidipine Study Group.
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S27-30. PubMed ID: 1726002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enalapril and atenolol in primary hypertension--a comparative study of blood pressure lowering and hormonal effects.
    Ohman KP; Karlberg BE
    Scand J Urol Nephrol Suppl; 1984; 79():93-7. PubMed ID: 6089325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
    Johnson AG; Pearce GL; Danoff TM
    J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metoprolol and atenolol administered once daily in primary hypertension. A clinical comparison of the efficacy of two selective beta-adrenoceptor blocking agents.
    Lyngstam O; Rydén L
    Acta Med Scand; 1981; 209(4):261-6. PubMed ID: 7015797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.
    Letellier P; Overlack A; Agnes E; Desche P
    J Hum Hypertens; 1994 Feb; 8(2):145-9. PubMed ID: 8207741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.